2007
DOI: 10.1016/j.atherosclerosis.2006.08.049
|View full text |Cite
|
Sign up to set email alerts
|

LipoCardium: Endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
55
0

Year Published

2007
2007
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 88 publications
(55 citation statements)
references
References 41 publications
0
55
0
Order By: Relevance
“…The use of endothelial target epitopes other than E-selectin, however, can be taken into account. Immunoliposomes directed toward VCAM-1 were internalized by activated endothelial cells in vitro (Voinea et al, 2005) and, in vivo, demonstrated beneficial effects in an atherosclerosis mouse model (Homem de Bittencourt et al, 2007). The use of VCAM-1-selective immunoliposomes in glomerulonephritis to interfere with microvascular endothelial cells distinct from the glomerular capillaries is an attractive strategy, especially because VCAM-1 is highly expressed throughout disease progression (Allen et al, 1999).…”
Section: Discussionmentioning
confidence: 99%
“…The use of endothelial target epitopes other than E-selectin, however, can be taken into account. Immunoliposomes directed toward VCAM-1 were internalized by activated endothelial cells in vitro (Voinea et al, 2005) and, in vivo, demonstrated beneficial effects in an atherosclerosis mouse model (Homem de Bittencourt et al, 2007). The use of VCAM-1-selective immunoliposomes in glomerulonephritis to interfere with microvascular endothelial cells distinct from the glomerular capillaries is an attractive strategy, especially because VCAM-1 is highly expressed throughout disease progression (Allen et al, 1999).…”
Section: Discussionmentioning
confidence: 99%
“…cyPGs bind to and modulate transcription factors (Cernuda-Morollón et al, 2001;Kim and Surh, 2006;Pérez-Sala, 2011), activate the antioxidant response (Levonen et al, 2004;Martínez et al, 2012), inactivate detoxifying enzymes like glutathione transferases (Sánchez-Gómez et al, 2010), and induce antiinflammatory and antiproliferative effects , for which they have been proposed as therapeutic tools (Fukushima et al, 2001;Homem de Bittencourt et al, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…cyPGs display varied biological effects, including antiproliferative and anti-inflammatory actions, for which a potential pharmacological use of these compounds has been put forward (Ianaro et al, 2003;Homem de Bittencourt et al, 2007). An important mechanism for cyPG action is the formation of covalent adducts with cellular proteins, resulting in altered protein function (Cernuda-Morollón et al, 2001;Pérez-Sala et al, 2003;Sá nchez-Gómez et al, 2004).…”
Section: Introductionmentioning
confidence: 99%